Company intelligence / Profile preview

CR Intrinsic Investments

Stamford, Connecticut, United States

Ownership: Private
Development stage: Other

Overview

CR Intrinsic Investors was a Stamford-based hedge fund advisory firm and a subsidiary of SAC Capital Advisors, founded by Steven A. Cohen. The firm is primarily known for its central role in a record-breaking $276 million insider trading scheme involving clinical trial results for the Alzheimer's drug bapineuzumab, which was being developed by Elan and Wyeth. In 2013, CR Intrinsic agreed to pay a $602 million settlement to the SEC, the largest insider trading settlement in history at the time. Following the legal fallout and the restructuring of SAC Capital into Point72 Asset Management, the firm ceased active operations. Its legacy remains a significant case study in the intersection of expert networks, clinical trial confidentiality, and financial regulation.

Industry: Investors

Beyond the preview

Go deeper on CR Intrinsic Investments.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CR Intrinsic Investments.

Explore the full profile